You work in the drug development division of a large pharmaceutical company. The current commercially available medicine for a heart condition works as an inhibitor of a beta receptor, which it binds to with the dissociation constant (Kd) of 10 nM. You designed a new drug candidate. To measure the binding affinity between the receptor and the drug candidate (ligand), you incubated the receptor with the ligand at various concentrations, and measured the fraction of receptor bound. The results are presented in the graph below. What is the value of the dissociation constant (Kd) for the new drug candidate, and did you succeed in designing a candidate that binds stronger than the available drug?